Schrodinger Inc (NAS:SDGR)
$ 20.59 0.01 (0.05%) Market Cap: 1.50 Bil Enterprise Value: 1.24 Bil PE Ratio: 0 PB Ratio: 3.16 GF Score: 78/100
Back to the Transcripts List

Q1 2024 Schrodinger Inc Earnings Call Transcript

May 01, 2024 / 08:30PM GMT
Release Date Price: $25.26 (+3.61%)

Key Points

Positve
  • Schrodinger Inc (SDGR) reported a solid start to the year with revenue growth meeting expectations.
  • The company announced IND clearance for STR. 35 15, expanding their clinical program portfolio.
  • Schrodinger Inc (SDGR) has seen a significant increase in hosted software revenue, growing more than 60% compared to Q1 last year.
  • The company continues to advance its proprietary pipeline with multiple clinical programs progressing.
  • Schrodinger Inc (SDGR) is actively developing computational solutions to predict drug toxicity risks, enhancing their scientific leadership in the industry.
Negative
  • Schrodinger Inc (SDGR) experienced a decrease in total revenue in Q1 2024 compared to Q1 2023, primarily due to lower drug discovery revenue.
  • The company's business in China has been below expectations this year, impacted by a challenging commercial environment.
  • Schrodinger Inc (SDGR) reported a net loss per diluted share of $0.76 in Q1 2024, compared to a profit in Q1 2023.
  • Operating loss increased significantly in Q1 2024 to $67 million, compared to $31 million in the same period a year ago.
  • The company's gross margin declined to 52% in Q1 2024 from 71% in Q1 2023, driven by lower drug discovery revenue.
Operator

Thank you for standing by, and welcome to Schrodinger's conference call to review first quarter and 2024 financial results. My name is Chloe, and I'll be your operator for today's call. Please be advised that this call is being recorded at the company's request.

Now, I would like to introduce your host for today's conference, Ms. Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden
Schrodinger Inc - Senior Vice President, Investor Relations & Corporate Communications

Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our first-quarter 2024 financial results.Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com.

Here with me on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer; and Karen Akinsanya, President of R&D and Therapeutics. Following our

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.